HTA252

Shorter time to decision for pharmaceuticals assessed in the Nordic HTA-collaboration, FINOSE

Jacob Gehrman, PhD[1]; Anna-Karin Boström, PhD[1]; Dominik Elsner, MSc[1]; Annabelle Forsmark, PhD[1]; Hanne Juuti, MSc[2]; Frida Labori, PhD[1]; Fredrik Olson, PhD[1] & Ida Sjöberg, MSc[1]

[1]PharmaLex Sweden AB, part of Cencora, Gothenburg, Sweden; [2]PharmaLex Finland Oy, part of Cencora, Vantaa, Finland

Background

- The HTA collaboration between Finland, Norway, and Sweden (FINOSE) joint assessment of pharmaceuticals is designed to inform the process of the reimbursement decisions in each of the three countries.
- Each country included in FINOSE makes a reimbursement decision on a national level.
- The aim of FINOSE is to support timely access to pharmaceuticals in the included countries and to achieve a processing time of 90 days (from submission to public assessment report).

Objectives

- To analyze time from marketing authorization (MA) to recommendation/reimbursement decision by national HTA authorities for the pharmaceuticals assessed within the FINOSE process.
- To extract the final recommendation/reimbursement decision by the national HTA authorities.
- To estimate the average time from MA to recommendation/reimbursement decision for pharmaceuticals **not included in FINOSE** i.e., that go through the individual national processes in Finland, Norway and Sweden.

Methods

- We extracted the dates for MAs, the FINOSE assessments, and the recommendation/reimbursement decisions from publicly-available sources at relevant HTA authorities. Additionally, the outcomes of the final decisions from the national HTA authorities were extracted.
- We extracted data regarding the time from local launch to public reimbursement (referred to here as “standard time”) from the Global Access to New Medicines Report (PhRMA, 2023). This was done to estimate the average time from MA to recommendation/reimbursement decision according to the national processes in Finland, Norway and Sweden, regardless of whether they were included in the FINOSE process.

Results

- From the start of FINOSE collaboration in 2018, four products have been assessed: atezolizumab (FINOSE, 2019a), enzalutamide (FINOSE, 2019b), betibeglogene autotemcel (FINOSE 2020) and atidarsagene autotemcel (FINOSE, 2022). The timelines for these pharmaceuticals are presented in **Figure 1**.
- The goal of 90 days processing time was not met for the pharmaceuticals assessed through FINOSE; the mean processing time was in fact 200 days.
- For all pharmaceuticals except atidarsagene autotemcel in Norway, the average time to recommendation/reimbursement decision through FINOSE was shorter than the standard time for each national process (the average time to recommendation/reimbursement decision varied between the countries, as illustrated in **Figure 2**).
- Recommendations were issued for Sweden and Norway for all products; of these, only two were positive (both atidarsagene autotemcel). In Finland only one decision was available and it was negative (betibeglogene autotemcel).

Conclusions

- Overall, time to market in the Nordics is faster for pharmaceutical products assessed through the FINOSE collaboration, compared to standard time.
- The goal of 90 days processing time was not met; the current mean processing time was more than double this goal (200 days).

Figure 1. Time from marketing authorization to decision: FINOSE applications



Figure 2. Difference in time to decision: FINOSE applications vs. standard time



Reference

PhRMA. *Global Access to New Medicines Report, 2023*. https://phrma.org/resource-center/Topics/Access-to-Medicines/Global-Access-to-New-Medicines-Report. April 11, 2023. Accessed: October 05, 2023

FINOSE. *Finose joint assessment report Tecentriq*, June 2019a. https://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/finose/previous-finose-assessments. June, 2019. Accessed: October 05, 2023

FINOSE. *Finose joint assessment report Xtandi*, 2019b. https://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/finose/previous-finose-assessments. June, 2019. Accessed: October 05, 2023

FINOSE. *Finose joint assessment report Zynteglo*, 2020. https://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/finose/previous-finose-assessments. June, 2020. Accessed: October 05, 2023

FINOSE. *Finose joint assessment report Libmeldy*, 2022. https://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/finose/previous-finose-assessments. February, 2022. Accessed: October 05, 2023

Presented at: ISPOR Annual European Congress;
12-15 November 2023; Copenhagen, Denmark.